HIV vaccine - Janssen

Drug Profile

HIV vaccine - Janssen

Alternative Names: HIV virus vaccine - Bavarian Nordic; Human human immunodeficiency virus vaccine - Bavarian Nordic; Modified Vaccinia Ankara Bavarian Nordic HIV vaccine; MVA-BN HIV; MVA-BN HIV vaccine - Bavarian Nordic

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bavarian Nordic
  • Developer Janssen
  • Class AIDS vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV-1 infections

Most Recent Events

  • 24 May 2018 Janseen plans a phase I trial in combination with AdVac in the second half of 2018
  • 29 Sep 2017 Preclinical trials in HIV-1 infections in USA (Parenteral) before September 2017 (Bavarian Nordic pipeline, September 2017)
  • 27 Jul 2017 Bavarian Nordic and Janssen expand their collaboration to develop vaccines for human immunodeficiency virus (HIV-1) and hepatitis B infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top